Literature DB >> 9544684

Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.

P L Jager1, B P Hazenberg, E J Franssen, P C Limburg, M H van Rijswijk, D A Piers.   

Abstract

UNLABELLED: In systemic amyloidosis, widespread amyloid deposition interferes with organ function, frequently with fatal consequences. Diagnosis rests on demonstrating amyloid deposits in the tissues, traditionally with histology although scintigraphic imaging with radiolabeled serum amyloid P component (SAP) has lately been developed as a specific noninvasive alternative. We report a detailed analysis of the abnormal turnover of SAP in patients with systemic amyloidosis and an assessment of its clinical value.
METHODS: Iodine-123-labeled human SAP (200 MBq) SAP was injected intravenously into 49 patients with histologically proven systemic AA- or AL- amyloidosis and in 7 control subjects. Plasma clearance and whole-body retention of labeled SAP were analyzed over 48 hr using plasma sampling, whole-body gamma camera imaging and measurement of radioactivity in the urine. The rate of SAP synthesis and interstitial exchange were determined, and the size of the amyloid compartment was compared with clinical estimates of whole-body amyloid load and patient survival.
RESULTS: All plasma time-activity curves were biphasic. In comparison with control subjects, patients with amyloidosis showed significantly faster plasma disappearance [4-hr value: AA 48% +/- 18%, AL 45% +/- 15% versus 65% +/- 8% (p < 0.05)], higher total-body retention 48 hr p.i. [AA 74% +/- 14%, AL 73% +/- 17% versus 46% +/- 15% (p < 0.01)] and especially higher extravascular retention 48 hr p.i. [AA 59% +/- 16%, AL 58% +/- 19% versus 30% +/- 14% (p < 0.01)]. Extravascular retention correlated with clinical estimation of the amyloid load. If extravascular retention values in patients with AL amyloidosis were over 60%, survival was decreased (median 4 versus 23 mo, p < 0.001). Markedly increased interstitial exchange rates were present in amyloidosis (AA 64 +/- 61, AL 50 +/- 37 versus 18 +/- 8 mg/hr), whereas the SAP synthesis rate did not differ from the control values (AA 5.0 +/- 3.0, AL 5.5 +/- 3.2 versus 4.5 +/- 1.4 mg/hr).
CONCLUSION: The presence of systemic amyloidosis is characterized by accelerated initial clearance of 123I-SAP from the plasma and increased interstitial exchange rate and extravascular retention. These findings reflect reversible binding of radiolabeled SAP to amyloid deposits and provide clinically useful information for diagnosis, monitoring of therapy and prognosis in patients with systemic amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544684

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Arie Oosterhof; Toin H van Kuppevelt; Nicole C Smits; Stephen J Kennel
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

3.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

4.  A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p.

Authors:  Michael J V White; Elkin Galvis-Carvajal; Richard H Gomer
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

5.  Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics.

Authors:  T M El Mansoury; B P C Hazenberg; S A El Badawy; A H Ahmed; J Bijzet; P C Limburg; M H van Rijswijk
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

6.  Efflux transport of serum amyloid P component at the blood-brain barrier.

Authors:  Szilvia Veszelka; Judit Laszy; Tamás Pázmány; László Németh; Izabella Obál; László Fábián; Gábor Szabó; Csongor S Abrahám; Mária A Deli; Zoltán Urbányi
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-11-21

Review 7.  Currents concepts on the immunopathology of amyloidosis.

Authors:  Anupama Bhat; Carlo Selmi; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

8.  Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis.

Authors:  Andor W J M Glaudemans; Riemer H J A Slart; Walter Noordzij; Rudi A J O Dierckx; Bouke P C Hazenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-09       Impact factor: 9.236

Review 9.  Nuclear imaging in cardiac amyloidosis.

Authors:  A W J M Glaudemans; R H J A Slart; C J Zeebregts; N C Veltman; R A Tio; B P C Hazenberg; R A J O Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-21       Impact factor: 9.236

Review 10.  From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature.

Authors:  Magdalena Dziadzio; Constantinos P Anastassiades; Philip N Hawkins; Michael Potter; Armando Gabrielli; Geraldine M Brough; Carol M Black; Christopher P Denton
Journal:  Clin Rheumatol       Date:  2005-03-02       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.